439607-87-1

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMOBENZO[D]OXAZOLE-2-THIOL is used as a building block for the synthesis of various compounds with potential therapeutic applications. Its unique structure and reactivity allow for the development of new molecules with specific biological activities, contributing to the discovery and advancement of novel pharmaceutical agents.
Used in Agrochemical Industry:
In the agrochemical sector, 5-BROMOBENZO[D]OXAZOLE-2-THIOL serves as a starting material for the synthesis of compounds with agricultural applications. Its properties enable the creation of molecules with pesticidal or herbicidal properties, enhancing crop protection and yield.
Used in Research and Development:
5-BROMOBENZO[D]OXAZOLE-2-THIOL is utilized as a research tool in the synthesis of novel molecules with potential uses in various fields. Its specific properties make it valuable for exploring new chemical reactions and pathways, facilitating the development of innovative compounds for diverse applications.

Upstream product

• 7693-52-9 4-bromo-2-nitrophenol 
• 75-15-0 carbon disulfide 
• 40925-68-6 2-amino-4-bromo-phenol 
• 140-89-6 potassium ethyl xanthogenate 

Relevant academic research and scientific papers

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane (CP-810,123), a novel α7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: Synthesis, SAR development, and in vivo efficacy in cognition models

A novel α7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4- diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that α7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia. 2009 American Chemical Society.

NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Disclosed are novel piperazine derivatives that act as agonists of the α7 nAChR. Also disclosed are phannaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds.

Pharmaceutical compositions for CNS and other disorders

The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant α7 nicotinic receptor agonist.

Pharmaceutical composition for the treatment of CNS and other disorders

The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharma

Benzoxazoline and benzimidazoline derivatives as novel aldose reductase inhibitors, part 2: Lead optimization

We designed novel aldose reductase inhibitors, benzoxazoline and benzimidazoline derivatives, based on lead evolution from spiroquinazolinones. In order to optimize in vivo activity in the lens, variously substituted derivatives were synthesized. The relationship between structure and in vitro activity was also analyzed by comparative molecular field analysis. The optimized compound exhibited high potency in the lens.